With Utah suffering the highest melanoma rate in the United States, Southern Utah University students are now helping rally a first line of defense: hairdressers who regularly look at people’s scalps, where the deadliest melanomas often form.
Posted in Melanoma News, Patients, Latest News
Ryan J. Sullivan, MD, associate director of Melanoma at the Massachusetts General Hospital, discusses the significance of the BRAF/MEK combination dabrafenib (Tafinlar) and trametinib (Mekinist), which was the first BRAF/MEK inhibitor regimen to be approved by the FDA for the treatment of patients with BRAF V600E–positive stage III melanoma following complete resection.
Posted in Melanoma News, Health Professionals, Video Reports
Patients with unresectable or metastatic BRAF V600-mutant melanoma who achieve a complete response (CR) to dabrafenib (Tafinlar) plus trametinib (Mekinist) are more likely to have improved survival outcomes at 5 years, according to a pooled analysis of data from the phase III COMBI-d and COMBI-v studies.1
Posted in Melanoma News, Health Professionals, Of Interest
The incidence of melanoma has increased to the head and neck by more than 50% in children, adolescents and young adults over the past nearly 20 years.
Posted in Melanoma News, Health Professionals, Of Interest
